PreveCeutical Announces Preliminary Screening Results of Peptides Derived From Blue Scorpion Venom in a Cell-Based Brain Cancer Model
PreveCeutical Medical Inc. (CSE:PREV) (OTC:PRVCF) (FSE:18H) (the “Company” or “PreveCeutical”), is pleased to announce positive results from the preliminary screening of key peptides from its scorpion venom-derived peptide research and development program (the “Peptide Program”), that is expected to enable the Company to generate Nature Identical peptide therapeutics intended for therapeutic applications. PreveCeutical’s initial focus is to understand the activities of such peptides in cell-based brain cancer models.
Through preliminary screening in a glioblastoma cell-based assay, PreveCeutical’s research team has successfully identified four lead peptides that inhibit the activity of a target protein implicit in the progression of certain aggressive brain cancers.
Further, the re-designed and synthesised peptides were found to be equally or more potent in the cell-based activity assay when compared to another scorpion peptide, Chlorotoxin. A series of more comprehensive screening assays are underway in the final stage of the Peptide Program, to allow the Company to develop a more detailed understanding of the activities of the peptides in progressively complex cell-based brain cancer models. No clinical studies have been planned to be undertaken at this time.
PreveCeutical’s President, Dr. Mak Jawadekar, commented, “This is a key milestone for PreveCeutical, as this research program underway in Queensland, Australia has successfully identified four lead peptides from blue scorpion venom.”
Dr. Harry Parekh, PreveCeutical’s Chief Research Officer commented, “We have identified novel, lead peptide candidates that inhibit activity of a key protein implicated in driving the aggressive nature of certain brain cancers. From a practical perspective, these lead peptides are attractive as they are a fraction of the size and complexity of an earlier reported scorpion-derived peptide, Chlorotoxin.”
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the soluble gel drug delivery program; Nature Identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company’s website.
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chairman and CEO
For further information, please contact:
Director of Corporate Communications & Investor Relations
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the ability of the Company to generate Nature Identical peptide therapeutics for therapeutic applications, to develop a more detailed understanding of the activities of the peptides in complex cell-based brain cancer models and the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise any therapeutics from the Company’s research programs, pursue business partnerships, complete its research programs as planned, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.